Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

CD40L (soluble) (human), (recombinant)

Increases the stimulation of B cells
ALX-522-015-C010 10 µg 208.00 USD
ALX-522-015-2010 2x10 µg 291.00 USD
ALX-522-015-6010 6x10 µg SuperPack 697.00 USD
Do you need bulk/larger quantities?

Product Details

Alternative Name:CD154, TNFSF 5, gp39
MW:~18kDa (SDS-PAGE).
Source:Produced in E. coli. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to a linker peptide (6 aa) and a FLAG®-tag.
UniProt ID:P29965
Concentration:0.1mg/ml after reconstitution.
Formulation:Lyophilized. Contains PBS.
Purity:≥95% (SDS-PAGE)
Purity Detail:Purified by Multi-Step Chromatography.
Endotoxin Content:<0.1EU/µg purified protein (LAL test; Associates of Cape Cod).
Specificity:Binds to human CD40.
Application Notes:ELISA: binds to CD40 receptor at 1-10 ng/ml.
Reconstitution:Reconstitute each tube with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein.
Shipping:Shipped on Blue Ice
Long Term Storage:-20°C
Use/Stability:Stable for at least 6 months after receipt when stored at -20°C.
Handling:Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
Technical Info/Product Notes:Historical data has shown that CD40L stimulates growth of B cells. The activity of rhsCD40L increases 1'000-fold (stimulation in the ng/ml range) in the presence of cross-linking enhancer (see Set Prod. No. ALX-850-064). For stimulation of mouse cells via CD40 use CD40L, Soluble (mouse) (recombinant) (Prod. No. ALX-522-070 or ALX-850-075).

FLAG is a registered trademark of Sigma-Aldrich Co.
Regulatory Status:RUO - Research Use Only
CD40L (soluble) (human), (recombinant) SDS-PAGE
SDS-PAGE Analysis of CD40L (soluble) (human), (recombinant). Lane 1: MW Marker, Lane 2: 1 µg.
CD40L (soluble) (human), (recombinant) Schematic structure
Schematic structure of human CD40L (peptide, aa. 116 to 261).
CD40L, soluble (human) (recombinant) set image
Figure 2: Stimulation of B cells by CD40L, Soluble (human) (rec.). Dose dependent costimulation of CD19+ cells by CD40L in the presence of 10ng/ml of IL-4 and of 2µg/ml anti-µ antibodies. Note that in the presence of enhancer (Prod. No. ALX-804-034), the activity of CD40L is increased >1’000 fold.Method: CD19+ cells were incubated in 96-well plates (105 cells/well in 100µl RPMI supplemented with 10% FCS) for 72 hours in the presence of 10ng/ml IL-4, 2µg/ml of goat anti-human µ chain antibody and with the indicated concentration of CD40L in the presence and absence of 1µg/ml enhancer (Prod. No. ALX-804-034). Cells were pulsed for an additional 6 hours with [3H]thymidine (1µCi/well) and harvested. [3H]thymidine incorporation was monitored by liquid scintillation counting."
Please mouse over
CD40L (soluble) (human), (recombinant) SDS-PAGE CD40L (soluble) (human), (recombinant) Schematic structure CD40L, soluble (human) (recombinant) set image

Product Literature References

BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy: R. Li, et al.; Acta Neuropathol. 143, 505 (2022), Abstract;
Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib: L. Rijvers, et al.; JCI Insight 7, e160909 (2022), Abstract;
Stage-Specific Non-Coding RNA Expression Patterns during In Vitro Human B Cell Differentiation into Antibody Secreting Plasma Cells: R.C. Tschumper, et al.; Noncoding RNA 8, 15 (2022), Abstract;
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy: H. Reimann, et al.; J. Immunother. Cancer 9, 2605 (2021), Abstract;
Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia: C. Schleiss, et al.; Leukemia 35, 1463 (2021), Abstract; Full Text
BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo: C. Schleiss, et al.; Sci. Rep. 9, 701 (2020), Abstract; Full Text
PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway: X. Wang, et al.; Mol. Immunol. 109, 20 (2019), Abstract;
Artesunate shows potent anti-tumor activity in B-cell lymphoma: T. K. Vatsveen, et al.; J. Hematol. Oncol. 11, 23 (2018), Abstract; Full Text
In vitro antineoplastic effects of auranofin in canine lymphoma cells: H. Zhang, et al.; BMC Cancer 18, 522 (2018), Abstract; Full Text
Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis: H. Masuda, et al.; J. Neuroimmunol. 316, 117 (2018), Abstract;
B-cell activation with CD40L or CpG measures the function of B-cell subsets and identifies specific defects in immunodeficient patients: E. Marasco, et al.; Eur. J. Immunol. 47, 131 (2017), Application(s): Human PBMC culture, Abstract; Full Text
CD40 signaling in Graves' disease is mediated through canonical and non-canonical thyroidal NF-κB activation: H.J. Lee, et al.; Endocrinology 158, 410 (2017), Abstract;
Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection: E.A. Miller, et al.; AIDS 29, 1287 (2015), Abstract; Full Text
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein: C. Jochems, et al.; Cancer Immunol. Immunother. 63, 161 (2014), Application(s): Stimulation of dendritic cells, Abstract;
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine: D.H. Hamilton, et al.; Oncotarget 4, 1777 (2013), Application(s): Stimulation of dendritic cells, Abstract; Full Text
Suppression by Δ9-tetrahydrocannabinol of the Primary Immunoglobulin M Response by Human Peripheral Blood B cells is Associated with Impaired STAT3 Activation: T. Ngaotepprutaram, et al.; Toxicology 310, 84 (2013), Application(s): Flow Cytometry, Abstract; Full Text
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role: J. Huang, et al.; Blood 120, 3030 (2012), Application(s): Cell Culture, Abstract; Full Text
Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function: J. Dannull, et al.; Blood 119, 3113 (2012), Application(s): Intracellular calcium release in human monocyte derived dendritic cells with Tecan Infinite plate reader, Abstract; Full Text
Targeting HIV-1 Envelope Glycoprotein Trimers to B Cells by Using APRIL Improves Antibody Responses: M. Melchers, et al.; J. Virol. 86, 2488 (2012), Application(s): Cell Culture, Abstract; Full Text
The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas: P. G. Knox, et al.; J. Cell Biol. 192, 391 (2011), Abstract; Full Text
Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand: E.H. Humphreys, et al.; PLoS One 5, e14037 (2010), Abstract; Full Text
Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas: L. Vardouli, et al.; Cancer Gene Ther. 16, 848 (2009), Application(s): Cell Culture, Abstract;
C4b Binding Protein Binds to CD154 Preventing CD40 Mediated Cholangiocyte Apoptosis: A Novel Link between Complement and Epithelial Cell Survival: K.T. Williams, et al.; PLoS ONE 2, e159 (2007), Application(s): Cell Culture, Abstract; Full Text
Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-kappaB Mutations or Activation of the CD30, CD40, and RANK Receptors: B. Zheng, et al.; Clin. Cancer Res. 10, 3207 (2004), Abstract;
HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection: S. Swingler, et al.; Nature 424, 213 (2003), Abstract; Full Text
Platelet-Activating Factor Mediates CD40-Dependent Angiogenesis and Endothelial-Smooth Muscle Cell Interaction: S. Russo, et al.; J. Immunol. 171, 5489 (2003), Abstract;
Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells: N. Harada, et al.; BBRC 299, 488 (2002), Abstract;
Suppression of IL-12 Production by Soluble CD40 Ligand: Evidence for Involvement of the p44/42 Mitogen-Activated Protein Kinase Pathway: M. Wittmann, et al.; J. Immunol. 168, 3793 (2002), Abstract;
Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling: S.P. Atamas, et al.; J. Immunol. 168, 1139 (2002), Abstract;
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines: P. Fiumara, et al.; Blood 98, 2784 (2001), Abstract; Full Text
Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells: G. Caron, et al.; J. Immunol. 167, 3682 (2001), Abstract;
CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway: J. Tan, et al.; J. Biol. Chem. 275, 37224 (2000), Abstract; Full Text
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity: P. Schneider, et al.; J. Exp. Med. 187, 12051 (1998), Abstract; Full Text

Related Products

CD40L, soluble (human) (recombinant) set 

Ligand plus enhancer for improved stability and enhanced immune activation.
Produced in E. coli. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to a linker peptide (6 aa) and a FLAG®-tag., ≥95% (SDS-PAGE)., FUNC | Print as PDF
ALX-850-064-KI01 1 Set 645.00 USD
Do you need bulk/larger quantities?

CD40L (soluble) (mouse), (recombinant) 

Produced in HEK 293 cells. The extracellular domain of mouse CD40L (CD154) (aa 115-260) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag., ≥90% (SDS-PAGE), ELISA | Print as PDF
ALX-522-070-C010 10 µg 306.00 USD
ALX-522-070-2010 2x10 µg 552.00 USD
Do you need bulk/larger quantities?

CD40L, soluble (mouse) (recombinant) set 

Produced in HEK 293 cells. The extracellular domain of mouse CD40L (CD154) (aa 115-260) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag., ≥90% (SDS-PAGE)., ELISA, FUNC | Print as PDF
ALX-850-075-KI01 1 Set 786.00 USD
Do you need bulk/larger quantities?

Enhancer for Ligands 

Enhances biological activity of TRAIL, soluble (human) (recombinant) and FasL, soluble (human) (recombinant).
Print as PDF
ALX-804-034-C050 50 µg 356.00 USD
Do you need bulk/larger quantities?

MEGACD40L® Protein (soluble) (human), (recombinant) 

High activity, high purity CD40L protein for co-stimulatory activation of an immune response
Produced in CHO cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag., ≥90% (SDS-PAGE) | Print as PDF
ALX-522-110-C010 10 µg 651.00 USD
Do you need bulk/larger quantities?

MEGACD40L® Protein (soluble) (mouse), (recombinant) 

High activity, high purity CD40L protein for co-stimulatory activation of an immune response
Produced in CHO cells. The extracellular domain of mouse CD40L (CD154) (aa 115-260) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag., ≥95% (SDS-PAGE) | Print as PDF
ALX-522-120-C010 10 µg 696.00 USD
Do you need bulk/larger quantities?

Product Toolbox


Certificate of Analysis


By target:
By biological activity:
CD40L Recombinant protein
By catalog section:


Technical Service
Customer Service